Edwyn
Over the last 5 years, Pfizer Inc has shown a consistent growth trend in its total assets, increasing from $154.2 billion in 2020 to $213.4 billion in 2024. This indicates the company's expansion and investment in its operations, possibly through acquisitions or increased research and development activities. However, there was a dip in total assets in 2023 compared to 2022, which could be attributed to various factors such as economic conditions, market dynamics, or strategic decisions. In terms of liabilities, Pfizer's total liabilities have also been on the rise, reaching $124.9 billion in 2024 from $90.8 billion in 2020. This increase suggests that the company has been utilizing debt to finance its growth initiatives or other capital requirements. The fluctuation in stockholders' equity is noteworthy, with a peak in 2022 at $95.7 billion before decreasing to $88.2 billion in 2024. This change could be due to factors like share repurchases, dividend payments, or fluctuations in the company's profitability. Overall, Pfizer's financial position appears robust, but monitoring the balance between debt and equity will be crucial for sustainable growth, especially in the competitive pharmaceutical industry.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.